メインナビゲーションにスキップ 検索にスキップ メインコンテンツにスキップ

Prognostic Impact of Initial Prostate-Specific Antigen in Metastatic Hormone-Sensitive Prostate Cancer Patients With Extensive Bone Metastases Under Androgen Receptor Signaling Inhibitor

  • Saizo Fujimoto
  • , Tsuyoshi Morita
  • , Yutaka Yamamoto
  • , Masanobu Saruta
  • , Atsuhiko Yoshizawa
  • , Kiyoshi Takahara
  • , Takuya Tsujino
  • , Ryoichi Maenosono
  • , Yuki Yoshikawa
  • , Wataru Fukuokaya
  • , Takafumi Yanagisawa
  • , Takahiro Kimura
  • , Takeshi Hashimoto
  • , Yosuke Hirasawa
  • , Yoshio Ohno
  • , Kazutoshi Fujita

研究成果: ジャーナルへの寄稿学術論文査読

抄録

Objectives: We evaluated the association between initial prostate-specific antigen (iPSA) levels and prognosis in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and extensive bone metastases treated with androgen receptor signaling inhibitors (ARSI). Subjects and Methods: This retrospective study included 276 de novo high-risk mHSPC patients with extensive bone metastases (extent of disease [EOD] score ≥ 2) who received ARSI as first-line therapy. The data were collected from institutions participating in the ULTRA Japan Study group. Patient data were collected from institutions affiliated with the ULTRAJ group. Patients were stratified into quartiles based on iPSA levels, and a cutoff value of 200 ng/mL was used for subgroup analysis. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan–Meier curves and Cox proportional hazards regression models. A restricted cubic spline analysis was conducted to evaluate the nonlinear association between iPSA levels and OS. Results: Kaplan–Meier analysis demonstrated significant associations between iPSA quartiles and OS (p = 0.030), with the lowest survival observed in the lowest iPSA group (Q1: < 200 ng/mL). A spline-based analysis suggested an inverted J-shaped association between iPSA and OS, with the lowest hazard ratio observed at 1664 ng/mL. Patients with iPSA < 200 ng/mL exhibited significantly shorter OS than those with higher levels (p = 0.015), while no significant difference in PFS was observed (p = 0.869). Conclusions: Initial PSA levels were associated with prognosis in high-risk mHSPC with extensive bone metastases. Although patients with relatively low iPSA had significantly shorter OS, those exhibited no significant difference in PFS, suggesting that patients with low iPSA could benefit from ARSI as the 1st line treatment.

本文言語英語
ページ(範囲)1307-1314
ページ数8
ジャーナルProstate
85
14
DOI
出版ステータス出版済み - 10-2025

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

  1. SDG 3 - すべての人に健康と福祉を
    SDG 3 すべての人に健康と福祉を

All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 泌尿器学

フィンガープリント

「Prognostic Impact of Initial Prostate-Specific Antigen in Metastatic Hormone-Sensitive Prostate Cancer Patients With Extensive Bone Metastases Under Androgen Receptor Signaling Inhibitor」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル